Clinical Trial Update: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy [Phase 4]

View source ↗

Summary

A Phase 4 trial of ENavogliflozin to alleviate ventricular diastolic dysfunction in Nonobstructive Hypertrophic Cardiomyopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonobstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• Enavogliflozin (enavogliflozin)

Snippet

Sponsor: Yonsei University | Conditions: Nonobstructive Hypertrophic Cardiomyopathy | Phase 4 | Status: RECRUITING